Relation Therapeutics: $300M valuation, IPO Readiness 53, Series B. Machine learning-driven drug discovery company mapping human disease biology at single-cell resolution. Track live on The IPO Stack.
Machine learning-driven drug discovery company mapping human disease biology at single-cell resolution.
Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.
Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.
Track Relation Therapeutics IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.
Relation Therapeutics has not publicly announced IPO plans. Track TechStackIPO for the latest signals and subscribe to The IPO Stack for weekly updates.
Relation Therapeutics is valued at $300M as of June 2022. This valuation is based on its most recent private funding round tracked by TechStackIPO.
Accredited investors can access Relation Therapeutics shares through secondary market platforms, pre-IPO investment funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace tracks available access options. Note: pre-IPO investments carry higher risk and limited liquidity compared to public market investing.
Relation Therapeutics scores 53/100 (Grade: D) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.
Relation Therapeutics has raised $50M in total venture capital and private equity funding, with backing from Foresite Capital, Founders Fund.
Relation Therapeutics's notable investors include Foresite Capital, Founders Fund. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.
Relation Therapeutics is a Biotechnology company. Machine learning-driven drug discovery company mapping human disease biology at single-cell resolution.